You are here
P2D, INC
UEI: KX3EAX2JEMV8
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD
Amount: $844,210.00ABSTRACTP2D Bioscience is developing a first-in-class treatment for Alzheimer’s disease (AD). Our drug is an orally-effective combination that targets both innate immunity and the dopamine transport ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Targeting Latexin for radiation mitigation.
Amount: $581,320.00The purpose of this grant is to develop novel therapeutic approaches for radiological/nuclear medical countermeasures. Very few medical products have been shown to counter the acute and long-term inju ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD
Amount: $504,565.00ABSTRACT The goal of this proposal is to develop tumor necrosis factorTNFinhibiting compounds as neuroprotectant drugs for treating Alzheimer s diseaseADCurrent FDA approved AD interventions are sympt ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
Activated protein C peptides for radio-mitigation
Amount: $591,344.00ABSTRACT The purpose of the proposed grant application is to further develop a therapeutic regimen focused on radiological nuclear medical countermeasuresVery few medical products have been shown to c ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment
Amount: $1,647,446.00ABSTRACT The goal of this proposal is to develop tumor necrosis factorTNFinhibiting compounds as neuroprotectant drugs for treating Alzheimer s diseaseADCurrent FDA approved AD interventions are sympt ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
PancreasCHIP- A diagnostic tool for Inheritable Pancreatic Disease
Amount: $266,046.00DESCRIPTION provided by applicant Pancreatitis is a painful condition that may become recurrent or chronic in genetically susceptible individuals Patients with pancreatitis suffer multiple hospita ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.
Amount: $1,489,893.00DESCRIPTION provided by applicant The goal of this proposal is to develop tumor necrosis factor a TNFa inhibiting compounds as neuroprotectant drugs for treating Alzheimerandapos s disease AD ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Novel Alzheimer's Disease Drug Treatment
Amount: $224,905.00DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (A ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML
Amount: $224,629.00DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the d ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
A non-myeloablative conditioning regimen for hematopoietic stem cell transplantat
Amount: $366,718.00Abstract Hematopoietic stem cell transplantation (HSCT) has become a standard care for the treatment of many hematologic malignancies and non-malignant diseases such as bone marrow failure and immunod ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health
